Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 07/29/26
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a BetZacks Investment Research • 07/21/26
Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026GlobeNewsWire • 07/15/26
Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin TreatmentInvestors Business Daily • 07/09/26
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 MonthsGlobeNewsWire • 07/08/26
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?The Motley Fool • 07/03/26
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) IndicationsGlobeNewsWire • 06/30/26
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2GlobeNewsWire • 06/29/26
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive StatusMarketBeat • 06/10/26
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical DermatologyGlobeNewsWire • 06/03/26
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewsWire • 05/26/26
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue EstimatesZacks Investment Research • 05/06/26
Arcutis Announces First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/06/26
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 04/29/26
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 MonthsGlobeNewsWire • 04/27/26
Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis GuidelinesGlobeNewsWire • 04/22/26
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026GlobeNewsWire • 04/15/26
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should KnowThe Motley Fool • 04/08/26
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 03/31/26
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/28/26